Case report of thrombotic thrombocytopenic purpura with severe acquired ADAM TS 13 deficiency in a previously healthy adult male
DOI:
https://doi.org/10.18203/2349-3933.ijam20251945Keywords:
Hemolytic anemia, Thrombocytopenia, Fever, Hematuria, Plasma exchangeAbstract
This was a 23 years old, previously healthy male, who presented with status epilepticus, fever and hematuria. Peripheral blood smear showed severe hemolytic anemia and thrombocytopenia. Thrombotic thrombocytopenic purpura (TTP) was suspected and treatment initiated with therapeutic plasma exchange and corticosteroids following which patient showed minimal improvement. Subsequently, blood reports showed critically low ADAM TS 13 activity, which confirmed the diagnosis of TTP. Plasmapheresis was continued along with methyl prednisolone and Rituximab, following which patient showed considerable clinical improvement.
Metrics
References
Scully M, Cataland S, Coppo P, Rubia J, Friedman K D, Hovinga JK, et al. International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-22. DOI: https://doi.org/10.1111/jth.13571
Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program. 2018;30(1):530-8. DOI: https://doi.org/10.1182/asheducation-2018.1.530
Kremer Hovinga JA, Coppo P, Lämmle B, Moake J L, Miyata T, Vanhooreelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;2:872. DOI: https://doi.org/10.1038/nrdp.2017.20
Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features and long-term outcomes from 1995 through 2015. Blood Adv. 2017;6;1(10):590-600. DOI: https://doi.org/10.1182/bloodadvances.2017005124
Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122(12):2023-9. DOI: https://doi.org/10.1182/blood-2013-04-496752
George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060-9. DOI: https://doi.org/10.1182/blood-2010-07-271445
Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med. 2010;49(1):7-15. DOI: https://doi.org/10.2169/internalmedicine.49.2706
Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163(4):514-9. DOI: https://doi.org/10.1111/bjh.12569
Changcharoen B, Bolger DT. Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody. BMJ Case Rep. 2015;2:136. DOI: https://doi.org/10.1136/bcr-2014-208477
Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, et al. Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591-6. DOI: https://doi.org/10.1007/s00277-009-0877-5
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. American Soc Hematol, 2017;129:2836-46. DOI: https://doi.org/10.1182/blood-2016-10-709857
Khabori M, Sayegh F, Yaseen H. The challenges in diagnosis and management of acquired thrombotic thrombocytopenic purpura: consensus report from three Gulf Countries. Oman Med J. 2022;37(4):407. DOI: https://doi.org/10.5001/omj.2022.32
Downloads
Published
How to Cite
Issue
Section
